Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9536)
All Articles published online
|
Publishing Process of This Article
|
Oct 15, 2013 (publication date) through Jun 5, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 2013; 4(5): 190-201 [PMID: 24147203 DOI: 10.4239/wjd.v4.i5.190] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v4/i5/190.htm |
| Number | Citing Articles |
| 1 |
Dhiren Patel. Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes. Journal of the American Association of Nurse Practitioners 2018; 30(1): S29 doi: 10.1097/JXX.0000000000000112
|
| 2 |
Nasreen Alfaris, Stephanie Waldrop, Veronica Johnson, Brunna Boaventura, Karla Kendrick, Fatima Cody Stanford. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. eClinicalMedicine 2024; 75: 102782 doi: 10.1016/j.eclinm.2024.102782
|
| 3 |
Vasilios Tsimihodimos, Theodosios D. Filippatos, Moses S. Elisaf. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opinion on Drug Metabolism & Toxicology 2017; 13(4): 399 doi: 10.1080/17425255.2017.1258055
|
| 4 |
David Seung U. Lee, Howard Lee, Irene Kretchy. Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide. Journal of Diabetes Research 2023; 2023: 1 doi: 10.1155/2023/7917641
|
| 5 |
Robyn Cunard. Endoplasmic Reticulum Stress in the Diabetic Kidney, the Good, the Bad and the Ugly. Journal of Clinical Medicine 2015; 4(4): 715 doi: 10.3390/jcm4040715
|
| 6 |
María José Pérez-Sáez, Mónica Marín-Casino, Julio Pascual. Treating posttransplantation diabetes mellitus. Expert Opinion on Pharmacotherapy 2015; 16(10): 1435 doi: 10.1517/14656566.2015.1039983
|
| 7 |
Ji Hyun Chun, Amy Butts. Long-acting GLP-1RAs. JAAPA 2020; 33(S8): 3 doi: 10.1097/01.JAA.0000669456.13763.bd
|
| 8 |
Aleksandra Szczesnowicz, Anna Szeliga, Olga Niwczyk, Gregory Bala, Blazej Meczekalski. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. Journal of Clinical Medicine 2023; 12(18): 5915 doi: 10.3390/jcm12185915
|
| 9 |
G. Penno, M. Garofolo, S. Del Prato. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrition, Metabolism and Cardiovascular Diseases 2016; 26(5): 361 doi: 10.1016/j.numecd.2016.01.001
|
| 10 |
Anna Gaddy, Mohamed Elrggal, Hector Madariaga, Adam Kelly, Edgar Lerma, Gates B Colbert. Diabetic Kidney Disease. Disease-a-Month 2025; 71(4): 101848 doi: 10.1016/j.disamonth.2024.101848
|
| 11 |
Songyan Wang, Bing Li, Chunguang Li, Wenpeng Cui, Lining Miao. Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy. Journal of Diabetes Research 2015; 2015: 1 doi: 10.1155/2015/962383
|
| 12 |
Stephen Thomas, Janaka Karalliedde. Diabetic nephropathy. Medicine 2015; 43(1): 20 doi: 10.1016/j.mpmed.2014.10.007
|
| 13 |
Mark M Smits, Lennart Tonneijck, Marcel H A Muskiet, Trynke Hoekstra, Mark H H Kramer, Indra C Pieters, Djuna L Cahen, Michaela Diamant, Daniël H van Raalte. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open 2015; 5(11): e009579 doi: 10.1136/bmjopen-2015-009579
|
| 14 |
Haoyu Peng, Junyi Ren, Yang Zhao, Xinyi Fang, Xiaoxiao Wang, Chi Liu, Zhengwei Wan. Unraveling the Connection between PCOS and renal Complications: Current insights and Future Directions. Diabetes Research and Clinical Practice 2025; 224: 112235 doi: 10.1016/j.diabres.2025.112235
|
| 15 |
Theodosios D Filippatos, Vasilios G Athyros, Moses S Elisaf. The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 2014; 10(6): 787 doi: 10.1517/17425255.2014.907274
|
| 16 |
Rufaida Wasim, Tarique Mahmood Ansari, Mohammed Haris Siddiqui, Farogh Ahsan, Arshiya Shamim, Aditya Singh, Mohammad Shariq, Aamir Anwar, Aquib Rehanullah Siddiqui, Saba Parveen. Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out
Cumulation. Hormone and Metabolic Research 2023; 55(01): 7 doi: 10.1055/a-1971-6965
|
| 17 |
Ruchi Chawla, Varsha Rani, Krishan Kumar, Mohini Mishra. Drug Repurposing Against SARS-CoV-2. 2023; : 1 doi: 10.2174/9789815123197123010004
|
| 18 |
Lindsay E. Clegg, Hiddo J.L. Heerspink, Robert C. Penland, Weifeng Tang, David W. Boulton, Srinivas Bachina, Robert D. Fox, Peter Fenici, Marcus Thuresson, Robert J. Mentz, Adrian F. Hernandez, Rury R. Holman. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. Diabetes Care 2019; 42(2): 318 doi: 10.2337/dc18-1871
|
| 19 |
Khaingthazin San, Joshua Fogel, Dmitriy Khazron. Retrospective Analysis of Hospitalized Patients with Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide 1 Receptor Agonist Therapy. Southern Medical Journal 2023; 116(2): 231 doi: 10.14423/SMJ.0000000000001511
|
| 20 |
Yijun Li, Ying Hu, Xiaoyuan Huyan, Kang Chen, Bing Li, Weijun Gu, Yiming Mu. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.1003263
|
| 21 |
Andrej Janez, Emir Muzurovic, Pawel Bogdanski, Leszek Czupryniak, Lubomira Fabryova, Zlatko Fras, Cristian Guja, Martin Haluzik, Peter Kempler, Nebojsa Lalic, Dana Mullerova, Anca Pantea Stoian, Nikolaos Papanas, Dario Rahelic, José Silva-Nunes, Tsvetalina Tankova, Volkan Yumuk, Manfredi Rizzo. Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group. Diabetes Therapy 2024; 15(9): 1865 doi: 10.1007/s13300-024-01615-5
|
| 22 |
Nesrain Mubarak Alhamedi. Exploring Side Effects and Discontinuation Reasons of Glucagon-Like-Peptide-1 Agonist (Liraglutide, Semaglutide) for Weight Loss Among Patients at King Abdulaziz University, Jeddah in 2021 to 2023. Journal of Clinical Medical Research 2025; : 1 doi: 10.46889/JCMR.2025.6104
|
| 23 |
Lawrence Blonde, Vivian Fonseca. Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits. Endocrine Practice 2018; 24: 8 doi: 10.4158/1934-2403-24.s2.1
|
| 24 |
Zhiyuan Cheng, Shuang Wang, Fu‐rong Li, Cheng Jin, Chunbao Mo, Jing Zheng, Xia Li, Fengchao Liang, Jinkui Yang, Dongfeng Gu. The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study. Journal of Diabetes 2024; 16(10) doi: 10.1111/1753-0407.70013
|
| 25 |
Donna Ryan, Andres Acosta. GLP‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity 2015; 23(6): 1119 doi: 10.1002/oby.21107
|
| 26 |
Giuseppe Coppolino, Christian Leporini, Laura Rivoli, Francesco Ursini, Eugenio Donato di Paola, Valeria Cernaro, Franco Arturi, Davide Bolignano, Emilio Russo, Giovambattista De Sarro, Michele Andreucci. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacological Research 2018; 129: 274 doi: 10.1016/j.phrs.2017.12.001
|
| 27 |
Mark Ayoub, Carol Faris, Tajana Juranovic, Harleen Chela, Ebubekir Daglilar. The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study. Cancers 2024; 16(9): 1625 doi: 10.3390/cancers16091625
|
| 28 |
Shichao Dong, Chuan Sun. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.1032199
|
| 29 |
Theodosios D. Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S. Elisaf. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgraduate Medicine 2019; 131(2): 82 doi: 10.1080/00325481.2019.1581971
|
| 30 |
Swetha R Reghunath, Ashna Chackochan, Girish Thunga, Dinesh U Acharya, Kaniyoor Nagri Shivashankara, Attur Ravindra Prabhu, Leelavathi D Acharya. Prevalence and Predictors of Adverse Events Associated With Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetic Patients: A Cross-sectional Study. Clinical Medicine Insights: Endocrinology and Diabetes 2024; 17 doi: 10.1177/11795514241288645
|
| 31 |
Markolf Hanefeld, Juan M. Arteaga, Lawrence A. Leiter, Giulio Marchesini, Elena Nikonova, Marina Shestakova, William Stager, Ricardo Gómez‐Huelgas. Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. Diabetes, Obesity and Metabolism 2017; 19(11): 1594 doi: 10.1111/dom.12986
|
| 32 |
Katherine A. Lyseng-Williamson. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features. Clinical Drug Investigation 2019; 39(8): 805 doi: 10.1007/s40261-019-00826-0
|
| 33 |
Arun K. Sharma, Punniyakoti V. Thanikachalam, Satyendra K. Rajput. Albiglutide: Is a better hope against diabetes mellitus?. Biomedicine & Pharmacotherapy 2016; 77: 120 doi: 10.1016/j.biopha.2015.12.015
|
| 34 |
Amar Puttanna, Lakshminarayanan Varadhan. Renal safety of newer medications. Practical Diabetes 2016; 33(3): 98 doi: 10.1002/pdi.2013
|
| 35 |
Jui-Ting Chang, Yao-Jen Liang, Chia-Yu Hsu, Chao-Yi Chen, Po-Jung Chen, Yi-Feng Yang, Yen-Lin Chen, Dee Pei, Jin-Biou Chang, Jyh-Gang Leu. Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells. BMC Pharmacology and Toxicology 2017; 18(1) doi: 10.1186/s40360-017-0172-3
|
| 36 |
Suzanne M. Boyle, Barbara Simon, Sidney M. Kobrin. Antidiabetic Therapy in End‐Stage Renal Disease. Seminars in Dialysis 2015; 28(4): 337 doi: 10.1111/sdi.12368
|
| 37 |
Thomas Idorn, Filip K. Knop, Morten B. Jørgensen, Tonny Jensen, Marsela Resuli, Pernille M. Hansen, Karl B. Christensen, Jens J. Holst, Mads Hornum, Bo Feldt-Rasmussen. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care 2016; 39(2): 206 doi: 10.2337/dc15-1025
|
| 38 |
André J. Scheen. Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes. Clinical Pharmacokinetics 2015; 54(1): 1 doi: 10.1007/s40262-014-0198-2
|
| 39 |
Dieter Ayers, Steve Kanters, Rachel Goldgrub, Monica Hughes, Ryo Kato, Nana Kragh. Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients. Current Medical Research and Opinion 2017; 33(9): 1653 doi: 10.1080/03007995.2017.1345730
|
| 40 |
Dilshani Jayawardene, Glenn M. Ward, David N. O’Neal, Geetha Theverkalam, Andrew I. MacIsaac, Richard J. MacIsaac. New Treatments for Type 2 Diabetes: Cardiovascular Protection Beyond Glucose Lowering?. Heart, Lung and Circulation 2014; 23(11): 997 doi: 10.1016/j.hlc.2014.05.007
|
| 41 |
Juan J. Gorgojo-Martínez, Gara Feo-Ortega, Clara Serrano-Moreno. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surgery for Obesity and Related Diseases 2016; 12(10): 1856 doi: 10.1016/j.soard.2016.02.013
|
| 42 |
Min-Hsiang Chuang, Jui-Yi Chen, Hsien-Yi Wang, Zheng-Hong Jiang, Vin-Cent Wu. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Network Open 2024; 7(8): e2427258 doi: 10.1001/jamanetworkopen.2024.27258
|
| 43 |
Juan P. Frias, Terry Dex, Michelle Roberts, Allen Kaplan. A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide. Diabetes Therapy 2019; 10(1): 21 doi: 10.1007/s13300-018-0547-5
|
| 44 |
Jianwen Wang, Jie Huang, Wei Li, Shiqi Tang, Jian Sun, Xianming Zhang, Jun Liu, Bin Yi, Jishi Liu, Xingfei Zhang, Qian Yang, Xiaoyan Yang, Shuang Yang, Guoping Yang, Hao Zhang. Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study. British Journal of Clinical Pharmacology 2019; 85(12): 2714 doi: 10.1111/bcp.14091
|
| 45 |
Jeppe Skov. Effects of GLP-1 in the Kidney. Reviews in Endocrine and Metabolic Disorders 2014; 15(3): 197 doi: 10.1007/s11154-014-9287-7
|
| 46 |
Heng-Chih Pan, Jui-Yi Chen, Hsing-Yu Chen, Fang-Yu Yeh, Chiao-Yin Sun, Thomas Tao-Min Huang, Vin-Cent Wu. GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nature Communications 2024; 15(1) doi: 10.1038/s41467-024-50199-y
|
| 47 |
Yu. V. Natochin, A. S. Marina, A. V. Kutina. The role of incretin as an integrator of sodium and water balance regulation. Doklady Biological Sciences 2014; 458(1): 271 doi: 10.1134/S0012496614050044
|
| 48 |
Okan Bakiner, M. Eda Ertorer. Diet and Nutrition in Critical Care. 2015; : 1283 doi: 10.1007/978-1-4614-7836-2_146
|
| 49 |
Nicole Felix, Mateus M. Gauza, Vinicius Bittar, Alleh Nogueira, Thomaz A. Costa, Amanda Godoi, Larissa Araújo de Lucena, Ocílio Ribeiro Gonçalves, Luís Cláudio Santos Pinto, Lucas Tramujas, José A. Moura-Neto, Maria Gabriela Guimarães. Cardiovascular and Kidney Outcomes of Glucagon-Like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Cardiorenal Medicine 2025; 15(1): 98 doi: 10.1159/000543149
|
| 50 |
Okan Bakiner, M. Eda Ertorer. Diet and Nutrition in Critical Care. 2014; : 1 doi: 10.1007/978-1-4614-8503-2_146-1
|
| 51 |
Justin Wan, Caesar Ferrari, Micheal Tadros. GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment. Gastroenterology Insights 2024; 15(1): 191 doi: 10.3390/gastroent15010014
|
| 52 |
Lance A. Sloan. Review of glucagon‐like peptide‐1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Journal of Diabetes 2019; 11(12): 938 doi: 10.1111/1753-0407.12969
|
| 53 |
Maggie M. Ramzy, Ahlam M. Abdalla, Nagwa M. Zenhom, Ahmed M. Okasha, Aya E. Abdelkafy, Rabeh K. Saleh. Therapeutic effect of liraglutide on expression of CTGF and BMP‐7 in induced diabetic nephropathy. Journal of Cellular Biochemistry 2019; 120(10): 17512 doi: 10.1002/jcb.29015
|
| 54 |
V. Sharmila Devi, Chitra Vellapandian, R. Ilavarasan, M. Sumithra. Role of Phytochemicals against Diabetic Nephropathy: An Insight into Molecular Receptors. Toxicology International 2023; : 585 doi: 10.18311/ti/2023/v30i4/30998
|
| 55 |
Jui-Yi Chen, Tsuen-Wei Hsu, Jung-Hua Liu, Heng-Chih Pan, Chun-Fu Lai, Shao-Yu Yang, Vin-Cent Wu. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials. American Journal of Kidney Diseases 2025; 85(5): 555 doi: 10.1053/j.ajkd.2024.11.013
|
| 56 |
Liselotte Fransson, Cristiane dos Santos, Petra Wolbert, Åke Sjöholm, Alex Rafacho, Henrik Ortsäter. Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome. Diabetology & Metabolic Syndrome 2014; 6(1) doi: 10.1186/1758-5996-6-3
|
| 57 |
Beatriz Rodríguez Jiménez, Pablo Rodríguez de Vera Gómez, Samuel Belmonte Lomas, Ángel Manuel Mesa Díaz, Irene Caballero Mateos, Irene Galán, Cristóbal Morales Portillo, María Asunción Martínez-Brocca. Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. Frontiers in Endocrinology 2024; 15 doi: 10.3389/fendo.2024.1386542
|
| 58 |
Iván Posso-Osorio, Carlos Julio Vargas-Potes, Mauricio Mejía, Carlos A. Cañas. Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature. Clinical Rheumatology 2023; 42(9): 2501 doi: 10.1007/s10067-023-06612-w
|
| 59 |
Blythe D. Shepard, Carolyn M. Ecelbarger. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Seminars in Nephrology 2021; 41(4): 331 doi: 10.1016/j.semnephrol.2021.06.005
|
| 60 |
Pajaree Krisanapan, Supawadee Suppadungsuk, Kanokporn Sanpawithayakul, Charat Thongprayoon, Pattharawin Pattharanitima, Supawit Tangpanithandee, Michael A Mao, Jing Miao, Wisit Cheungpasitporn. Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis. Clinical Kidney Journal 2024; 17(2) doi: 10.1093/ckj/sfae018
|
| 61 |
Theodosios D. Filippatos, Evangelos N. Liberopoulos, Moses S. Elisaf. Dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism 2015; 6(1): 29 doi: 10.1177/2042018814558243
|
| 62 |
Habib Yaribeygi, Stephen L. Atkin, Fabrizio Montecucco, Tannaz Jamialahmadi, Amirhossein Sahebkar, Naoaki Sakata. Renoprotective Effects of Incretin‐Based Therapy in Diabetes Mellitus. BioMed Research International 2021; 2021(1) doi: 10.1155/2021/8163153
|
| 63 |
Victoria J. Riehl-Tonn, Kyle D. Medak, Christie Rampersad, Anne MacPhee, Tyrone G. Harrison. GLP-1 Agonism for Kidney Transplant Recipients: A Narrative Review of Current Evidence and Future Directions Across the Research Spectrum. Canadian Journal of Kidney Health and Disease 2024; 11 doi: 10.1177/20543581241290317
|
| 64 |
Kenneth Blum, Catherine A. Dennen, Kai-Uwe Lewandrowski, Alireza Sharafshah, Albert Pinhasov, Abdalla Bowirrat, Igor Elman, Jean Lud Cadet, Eric R. Braverman, Panayotis K. Thanos, Milan Makale, David Baron, J.Wesson Ashford, Brian Fuehrlein, Nicole Avena, Eliot Gardner, Rajendra D. Badgaiyan, Marjorie Gondré—Lewis, Edward J. Modestino, Jag Khalsa, Kevin T. Murphy, Keerthy Sunder, Zeine Foojan, Nicole Jafari, Paul R. Carney, Rene Cortes, Drew Edwards, A.Kenison Roy III, David E. Smith, Mark S. Gold. Hypothesizing glucagon-like peptide 1 (GLP-1), agonists promote hypodopaminergia, resulting in heightened addictive reward-seeking and altered mood: Breaking the bubble and adding salt to a wound. Medical Hypotheses 2025; 198: 111612 doi: 10.1016/j.mehy.2025.111612
|
| 65 |
Gerhard H. Scholz, Holger Fleischmann. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Therapeutic Advances in Endocrinology and Metabolism 2014; 5(5): 95 doi: 10.1177/2042018814556099
|
| 66 |
Jingyi Guo, Maoying Wei, Wenhua Zhang, Yijia Jiang, Aijing Li, Churan Wang, Dan Yin, Anning Sun, Yanbing Gong. Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1517272
|
| 67 |
Giorgio Gentile, Daniela Mastroluca, Piero Ruggenenti, Giuseppe Remuzzi. Novel effective drugs for diabetic kidney disease? or not?. Expert Opinion on Emerging Drugs 2014; 19(4): 571 doi: 10.1517/14728214.2014.979151
|
| 68 |
M. H. A. Muskiet, L. Tonneijck, M. M. Smits, M. H. H. Kramer, M. Diamant, J. A. Joles, D. H. van Raalte. Acute renal haemodynamic effects of glucagon‐like peptide‐1 receptor agonist exenatide in healthy overweight men. Diabetes, Obesity and Metabolism 2016; 18(2): 178 doi: 10.1111/dom.12601
|
| 69 |
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Robert S Busch, Alan G Zimmermann, D Bradley Woodward, Fady T Botros. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The Lancet Diabetes & Endocrinology 2018; 6(8): 605 doi: 10.1016/S2213-8587(18)30104-9
|
| 70 |
Sebastian Filippas-Ntekouan, Theodosios D. Filippatos, Moses S. Elisaf. SGLT2 inhibitors: are they safe?. Postgraduate Medicine 2018; 130(1): 72 doi: 10.1080/00325481.2018.1394152
|
| 71 |
Kunz Martinez Walter, Perez Pacheco Arturo Ivan. The privileged position of glp-1 in diabetic nephropathy. Endocrinology&Metabolism International Journal 2018; 6(3) doi: 10.15406/emij.2018.06.00182
|
| 72 |
Hsuan-Wen Lai, Chun Yin See, Jui-Yi Chen, Vin-Cent Wu. Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists. Cardiovascular Diabetology 2024; 23(1) doi: 10.1186/s12933-024-02364-2
|